Methods and materials for identifying and treating membranous nephropathy
US-2024353404-A1 · Oct 24, 2024 · US
Passive immunization for staphylococcus infections
US2016311925A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016311925-A1 |
| Application number | US-201415104104-A |
| Country | US |
| Kind code | A1 |
| Filing date | Dec 15, 2014 |
| Priority date | Dec 13, 2013 |
| Publication date | Oct 27, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are monoclonal antibodies or binding portion thereof that bind specifically to a Staphylococcus spp. autolysin N-acetylmuramoyl-L-alanine amidase catalytic domain and/or cell wall binding domain, as well as pharmaceutical compositions containing the same. Cell lines expressing the monoclonal antibodies, including hybridomas, are also disclosed. Methods of using the monoclonal antibodies for installation of orthopedic implants, grafts or medical devices, treating or preventing a Staphylococcus infection, and treating osteomyelitis are described, as are diagnostic methods for the detection of Staphylococcus in a sample.
First claim
Opening claim text (preview).
What is claimed is: 1 . A monoclonal antibody, or binding portion thereof, that binds specifically to a Staphylococcus spp. autolysin consensus N-acetylmuramoyl-L-alanine amidase (Amd) catalytic domain and/or cell wall binding domain. 2 . The monoclonal antibody, or Amd binding portion thereof, according to claim 1 , wherein the monoclonal antibody or Amd binding portion inhibits in vivo growth of a Staphylococcus strain and/or biofilm establishment on…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016311925A1 cover?
- Disclosed herein are monoclonal antibodies or binding portion thereof that bind specifically to a Staphylococcus spp. autolysin N-acetylmuramoyl-L-alanine amidase catalytic domain and/or cell wall binding domain, as well as pharmaceutical compositions containing the same. Cell lines expressing the monoclonal antibodies, including hybridomas, are also disclosed. Methods of using the monoclonal…
- Who is the assignee on this patent?
- Univ Rochester
- What technology area does this patent fall under?
- Primary CPC classification C07K16/40. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Oct 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).